Ophthalmology – Steroid-Induced Glaucoma

What the Disorder Represents

Steroid-induced glaucoma is a secondary open-angle glaucoma caused by corticosteroid-related reduction in aqueous outflow through the trabecular meshwork.

The sequence is:

Corticosteroid exposure → increased trabecular outflow resistance → elevated IOP → glaucomatous optic nerve damage if sufficiently severe or prolonged

An important distinction is:

• Steroid-induced ocular hypertension = IOP elevation without glaucomatous damage
• Steroid-induced glaucoma = IOP elevation with characteristic optic neuropathy and/or visual-field loss

Which Steroids Can Cause It

Virtually any corticosteroid route can produce an IOP response, including:

• Topical ophthalmic drops
• Periocular injections
• Intravitreal injections
• Intravitreal steroid implants
• Systemic corticosteroids
• Inhaled corticosteroids
• Intranasal corticosteroids
• Dermatologic preparations, particularly when applied around the eyelids

Risk varies considerably according to:

• Steroid potency
• Dose
• Duration
• Route
• Individual susceptibility

Which Routes Carry the Greatest Ocular Risk

The largest and most prolonged IOP elevations are often seen with:

• Intravitreal corticosteroids
• Sustained-release intraocular steroid implants
• Periocular depot steroids

Topical ophthalmic steroids are also a common cause because they are frequently prescribed.

Systemic, inhaled, intranasal, and dermatologic formulations generally carry lower ocular risk but can still cause clinically important IOP elevation in susceptible patients.

What Is a Steroid Responder?

A steroid responder is a patient who develops a clinically meaningful rise in IOP after corticosteroid exposure.

Responses range from:

• Minimal
• Moderate
• Marked

A small proportion of the general population are:

High steroid responders

and may develop substantial IOP elevations even with relatively short treatment courses.

Who Is Most Susceptible

Risk is increased in patients with:

• Primary open-angle glaucoma
• Ocular hypertension
• First-degree family history of glaucoma
• Previous steroid-induced IOP elevation
• High baseline IOP
• High myopia
• Diabetes mellitus
• Young children
• Older adults

Patients with advanced pre-existing glaucoma are particularly vulnerable because even a moderate additional IOP rise may cause further damage.

Why Children Require Special Attention

Children can develop:

• Rapid
• Large
• Occasionally asymptomatic

IOP elevations after topical or systemic corticosteroids.

This is particularly important when steroids are prescribed for:

• Uveitis
• Vernal keratoconjunctivitis
• Postoperative inflammation
• Dermatologic disease around the eyes

IOP monitoring should not be omitted simply because the patient is young.

How Steroids Raise IOP

Corticosteroids act through glucocorticoid receptors in trabecular meshwork cells and produce several changes that reduce aqueous outflow.

These include:

• Increased extracellular matrix deposition
• Altered actin cytoskeleton
• Reduced trabecular meshwork phagocytosis
• Reduced degradation of extracellular material
• Altered cell-cell and cell-matrix adhesion
• Increased expression of proteins such as myocilin

The result is:

Higher resistance to aqueous passage through the conventional outflow pathway.

Relationship to Myocilin

Corticosteroids can increase:

MYOC/myocilin expression

in trabecular meshwork cells.

MYOC mutations are also associated with:

• Juvenile open-angle glaucoma
• Some adult-onset open-angle glaucoma

However, steroid-induced glaucoma itself is not simply a MYOC mutation disorder.

When IOP Usually Starts to Rise

With topical ophthalmic corticosteroids, IOP commonly begins to rise after approximately:

2–6 weeks

although elevation can occur:

• Within days in highly susceptible patients
• Much later during chronic treatment

Depot or sustained-release intraocular steroid preparations may cause elevation:

Weeks to months after administration

and the effect may persist for a prolonged period.

Why Timing Can Be Misleading

A patient may develop steroid-related IOP elevation even after:

• Months of apparently safe treatment
• Repeated previous steroid courses without difficulty

Therefore a normal early IOP does not eliminate later risk.

What Happens After Steroids Are Stopped

After discontinuing topical corticosteroids, IOP often returns toward baseline over:

Days to several weeks

However, normalization may take longer after:

• Long-term exposure
• Depot injections
• Intravitreal implants

Some patients with underlying glaucoma may continue to require treatment even after the steroid effect resolves.

Why Route and Molecule Matter

More potent ocular steroids generally have a greater tendency to raise IOP.

Higher-risk agents include:

• Dexamethasone
• Prednisolone acetate
• Difluprednate

Agents with a generally lower propensity for IOP elevation include:

• Loteprednol
• Fluorometholone

However:

No corticosteroid is completely free of steroid-response risk.

Why Loteprednol Is Often Chosen

Loteprednol is designed to undergo rapid metabolism after exerting its anti-inflammatory action.

This tends to produce:

A lower average risk of clinically significant IOP elevation

than stronger ketone corticosteroids such as prednisolone or dexamethasone.

It is still capable of raising IOP in susceptible patients.

What Patients Usually Notice

Most patients with steroid-induced ocular hypertension are:

Asymptomatic

even when IOP is significantly elevated.

When IOP becomes very high, symptoms may include:

• Ocular discomfort
• Headache
• Blurred vision
• Halos

But absence of symptoms provides:

No reassurance that the IOP is normal.

History That Should Always Be Taken

Ask specifically about every possible corticosteroid source:

• Eye drops
• Intravitreal injections
• Periocular injections
• Oral steroids
• IV steroids
• Inhalers
• Nasal sprays
• Skin creams
• Joint injections
• Steroid implants

Patients may not recognize inhalers or skin creams as:

Steroid exposure.

What the Examination Usually Shows

Typical findings include:

• Elevated IOP compared with baseline
• Open anterior chamber angle
• Otherwise relatively quiet anterior segment if there is no underlying inflammatory disease

If glaucoma has developed, the optic nerve may show:

• Neuroretinal rim thinning
• Focal notching
• RNFL defects
• Disc hemorrhage

Gonioscopy Findings

Gonioscopy typically shows:

An open angle

because the mechanism is increased trabecular resistance rather than angle closure.

Gonioscopy is important to exclude:

• Angle closure
• Neovascularization
• Trauma-related angle recession
• Other secondary glaucoma mechanisms

Optic Nerve Evaluation

Look for classic glaucomatous abnormalities including:

• Focal rim thinning
• Superior or inferior notching
• Increased vertical cup-to-disc ratio
• RNFL defects
• Disc hemorrhage

The appearance is generally indistinguishable from:

Primary open-angle glaucoma.

OCT Assessment

Modern structural evaluation includes:

• Peripapillary RNFL OCT
• Macular ganglion cell/inner plexiform layer analysis
• Optic nerve photography when useful

These help establish whether elevated IOP has already caused:

Glaucomatous structural damage.

Visual Field Testing

Standard automated perimetry should be performed when:

• IOP elevation is significant
• The optic nerve appears suspicious
• Pre-existing glaucoma is present

Typical field defects include:

• Nasal step
• Paracentral defect
• Arcuate scotoma

Why Pachymetry Is Useful

Central corneal thickness affects interpretation of:

Applanation IOP

but should not be used as a simple mathematical correction factor.

It contributes to overall glaucoma risk assessment rather than providing a precise “corrected IOP.”

Distinguishing Steroid-Induced Glaucoma From POAG

The two conditions can look almost identical.

Clues favoring a steroid effect include:

• Temporal relationship to corticosteroid exposure
• Previous normal IOP
• IOP reduction after steroid reduction or cessation
• Marked elevation during steroid therapy

Some patients have both:

Underlying POAG plus an additional steroid response.

Distinguishing It From Uveitic Glaucoma

This is a common diagnostic challenge.

A patient being treated for uveitis may have high IOP because of:

Steroid Effect

• Usually open angle
• Often develops after steroid exposure
• Eye may be relatively quiet

Active Uveitis

IOP elevation may result from:

• Trabeculitis
• Inflammatory debris
• Peripheral anterior synechiae
• Pupillary block
• Other inflammatory mechanisms

In many patients:

Both mechanisms contribute simultaneously.

Do Not Stop Necessary Steroids Reflexively

If the patient is being treated for:

• Severe uveitis
• Scleritis
• Postoperative inflammation
• Systemic autoimmune disease

abrupt steroid cessation may be harmful.

The goal is instead to balance:

Inflammatory control and IOP control.

First Management Step

When medically possible:

Reduce, discontinue, or replace the corticosteroid

with a less IOP-provoking alternative.

Possible strategies include:

• Lower dose
• Lower frequency
• Shorter course
• Switch to loteprednol or another lower-risk steroid
• Introduce steroid-sparing therapy for chronic inflammatory disease

This should be coordinated with the clinician treating the underlying condition.

First-Line IOP-Lowering Medication

Treatment generally follows principles used for other open-angle glaucomas.

Common options include:

• Topical beta-blockers
• Topical carbonic anhydrase inhibitors
• Alpha-2 agonists
• Prostaglandin analogues

Choice depends on:

• Magnitude of IOP elevation
• Comorbidities
• Underlying ocular inflammation

Beta-Blockers

Examples include:

• Timolol
• Betaxolol

These reduce aqueous production.

Avoid or use cautiously in patients with:

• Asthma
• Significant COPD
• Bradycardia
• Heart block

Topical Carbonic Anhydrase Inhibitors

Useful agents include:

• Dorzolamide
• Brinzolamide

They reduce aqueous secretion and are frequently used in:

• Steroid-induced ocular hypertension
• Uveitic glaucoma

Alpha-2 Agonists

Brimonidine can provide additional IOP reduction.

Potential limitations include:

• Allergic follicular conjunctivitis
• Fatigue
• Dry mouth

It should generally be avoided in:

Young children

because of CNS depression risk.

Prostaglandin Analogues

Agents such as:

• Latanoprost
• Travoprost
• Bimatoprost
• Tafluprost

are effective IOP-lowering medications and can be used in many patients with steroid-induced glaucoma.

Older concerns that prostaglandins routinely trigger:

• Uveitis
• CME

appear to have been overstated, although caution may still be reasonable in selected patients with:

• Active severe inflammation
• Recent complicated intraocular surgery
• Prior herpetic keratouveitis

Combination Drops

Fixed combinations can improve adherence when multiple medications are required.

Examples include:

• Dorzolamide/timolol
• Brimonidine/timolol
• Brinzolamide/brimonidine

Choice should be individualized.

When Oral Acetazolamide Is Useful

For substantial or rapidly rising IOP, systemic carbonic anhydrase inhibition may be used temporarily.

Acetazolamide can rapidly reduce aqueous production.

Use cautiously in patients with:

• Renal impairment
• Electrolyte disturbances
• Sulfonamide-related severe drug reactions
• Certain metabolic conditions

Hyperosmotic Therapy

Agents such as IV mannitol are:

Not routine therapy for chronic steroid-induced glaucoma

but may be considered for a severe acute IOP crisis when rapid temporary reduction is required.

Selective Laser Trabeculoplasty

SLT can be effective in steroid-induced ocular hypertension or glaucoma, particularly when:

• The angle is open
• Chronic corticosteroid exposure must continue
• Medication burden is high

It can reduce dependence on topical therapy.

Why SLT Can Be Especially Useful

The trabecular meshwork is the primary site of steroid-induced outflow resistance.

SLT can therefore improve:

Trabecular aqueous outflow

without requiring steroid withdrawal.

Its effectiveness varies among patients.

When Surgery Is Needed

Surgery is considered when IOP remains uncontrolled despite:

• Steroid modification
• Medical therapy
• Laser treatment

or when optic nerve damage is advancing.

Surgical Options

Depending on severity and ocular anatomy, options may include:

• Trabeculectomy
• Glaucoma drainage device
• Angle-based procedures/MIGS in selected patients
• Goniotomy or trabeculotomy, particularly in selected pediatric cases

More severe or inflammatory cases may require:

Trabeculectomy or tube-shunt surgery.

MIGS in Steroid-Induced Glaucoma

Because the angle is usually open, selected patients may benefit from procedures targeting the conventional outflow pathway.

These may include:

• Trabecular bypass
• Goniotomy
• Trabeculotomy-based procedures

They are most appropriate when:

• Disease is not extremely advanced
• Target IOP is compatible with MIGS capability

Monitoring Before Starting Steroids

Whenever significant or prolonged corticosteroid therapy is planned, ideally document:

• Baseline IOP
• Optic nerve status
• Glaucoma history

Baseline OCT and visual fields are useful when:

• Glaucoma already exists
• Long-term potent steroid therapy is anticipated

Monitoring After Starting Topical Steroids

A practical approach is to check IOP:

• At baseline when possible
• After approximately 2–4 weeks
• Again during continued therapy

High-risk patients may need:

Earlier and more frequent monitoring.

There is no single schedule appropriate for every patient.

Monitoring After Depot or Intravitreal Steroids

Patients receiving:

• Intravitreal triamcinolone
• Dexamethasone implant
• Fluocinolone implants
• Periocular depot steroids

may require:

Longer and more frequent surveillance

because IOP elevation can be delayed and prolonged.

Follow-up should reflect the known pharmacologic duration of the particular preparation.

Patients With Existing Glaucoma

If the patient already has glaucoma, management should aim to maintain IOP at or below the individual’s:

Established target pressure

rather than accepting a generic value such as 30 mm Hg.

Even relatively modest IOP elevation may be unacceptable in advanced disease.

Why a Fixed IOP Threshold Is Misleading

Older recommendations sometimes used a universal threshold such as:

IOP <30 mm Hg

for patients without apparent damage.

Modern glaucoma care is more individualized.

Treatment intensity depends on:

• Baseline IOP
• Duration of elevation
• Optic nerve susceptibility
• Existing glaucoma
• Rate of progression
• Age and life expectancy

How Treatment Response Is Followed

Monitor:

• IOP
• Optic nerve appearance
• RNFL/GCC OCT
• Visual fields
• Medication adherence
• Steroid dose and route

In patients on long-term corticosteroids, monitoring should continue even after an initially normal response.

When Urgent Treatment Is Needed

More urgent intervention is appropriate when there is:

• Very high IOP
• Rapid rise from baseline
• Advanced glaucoma
• New visual field loss
• Progressive OCT damage
• Corneal edema from high pressure

Expected Outcome

Prognosis is generally excellent when:

• The IOP rise is detected early
• Steroid exposure is modified
• Pressure is adequately controlled

Steroid-induced ocular hypertension is often:

Reversible

but glaucomatous optic nerve damage is:

Permanent.

When IOP May Remain Elevated

Persistent glaucoma is more likely when:

• Steroid exposure was prolonged
• IOP was markedly elevated
• The patient already had POAG
• Structural optic nerve damage developed

Such patients may require lifelong glaucoma treatment.

Potential Complications

Untreated or inadequately controlled disease can cause:

• RNFL loss
• Progressive optic nerve cupping
• Arcuate visual field defects
• Paracentral field loss
• Peripheral field constriction
• Irreversible visual impairment

High-Yield Takeaways

• Steroid-induced glaucoma is a secondary open-angle glaucoma caused by corticosteroid-related reduction in trabecular aqueous outflow.
• Elevated IOP without optic nerve damage is better termed steroid-induced ocular hypertension.
• Any corticosteroid route can cause an IOP rise, including topical, periocular, intravitreal, systemic, inhaled, intranasal, and periocular dermatologic preparations.
• Major risk factors include pre-existing POAG, ocular hypertension, family history of glaucoma, previous steroid response, high myopia, diabetes, and young age.
• Topical steroid-associated IOP elevation most commonly appears after 2–6 weeks, but susceptible patients may respond much sooner.
• Intravitreal injections and long-acting steroid implants can produce delayed and prolonged IOP elevation.
• More potent steroids such as dexamethasone, prednisolone acetate, and difluprednate generally carry greater risk than agents such as loteprednol.
• The mechanism is primarily increased trabecular meshwork resistance from extracellular matrix, cytoskeletal, and cellular changes.
• The anterior chamber angle is typically open on gonioscopy.
• The optic nerve and visual-field pattern are essentially indistinguishable from primary open-angle glaucoma.
• In uveitis, always distinguish steroid response from inflammation-related IOP elevation; both can coexist.
• The first management step is to reduce, stop, or switch the corticosteroid when medically safe, but necessary anti-inflammatory therapy should not be withdrawn indiscriminately.
• Topical glaucoma therapy commonly includes beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists, and prostaglandin analogues.
• SLT is an effective option in selected patients, particularly when corticosteroid treatment must continue.
• Refractory disease may require MIGS, trabeculectomy, or a glaucoma drainage device, depending on disease severity.
• Patients starting prolonged ocular corticosteroids should ideally have a baseline IOP and subsequent IOP monitoring, with closer surveillance for high-risk patients.
• A fixed IOP threshold such as 30 mm Hg is not an appropriate universal treatment target; management should be based on individual glaucoma risk and target IOP.
• Steroid-induced IOP elevation may reverse after treatment is stopped, but glaucomatous optic nerve damage is irreversible, making early detection essential.